POSTER SESSION 4

Tuesday June 14, 2016: 12:45-14:15
Exhibition Space (30 Euston Square)

PS4

PS4-1

COSTS OF FIRST-LINE TREATMENT FOR ELDERLY MULTIPLE MYELOMA PATIENTS WHO ARE NOT TRANSPLANT CANDIDATES IN THE SERBIAN HEALTH CARE SYSTEM
Durda Vukicevic, MD, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, Hall in Tyrol, Austria, Ursula Rochau, MD, MSc, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and HTA, Department of Public Health and HTA/ ONCOTYROL - Center for Personalized Cancer Medicine, Area 4 HTA and Bioinformatics, Hall in Tyrol/ Innsbruck, Austria, Aleksandar Savic, MD, PhD, Clinic for hematology, Clinical Center of Vojvodina, Medical Faculty, University of Novi Sad, Novi Sad, Serbia, Monika Buchberger, MSc, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, Hall i.T., Austria, Milica Jevdjevic, DMD, Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i. T., Austria, Gaby Sroczynski, MPH, Dr.PH, UMIT - University for Health Sciences, Medical Informatics and Technology, Institute of Public Health, Medical Decision Making and HTA, Department of Public Health, Health Services Research and HTA/ ONCOTYROL - Area 4, HTA and Bioinformatics, Hall i.T./Innsbruck, Austria and Uwe Siebert, MD, MPH, MSc, ScD, UMIT, Hall in Tirol (Austria) / Boston (USA), Austria
PS4-2

A RAPID INFLUENZA TEST IN HOSPITALS COULD AVOID UNNECESSARY PAEDIATRIC ISOLATION BED DAYS AND SAVE COSTS
Elisabeth Adams1, Rebecca Glover1, Andres Vecino Ortiz1, Sam Douthwaite2 and Simon Goldenberg2, (1)Aquarius Population Health, London, United Kingdom, (2)Guy's and St Thomas' NHS Trust, London, United Kingdom
PS4-3

BUDGET IMPACT ANALYSIS INCLUDING OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR FOR THE TREATMENT OF CHRONIC HEPATITIS C IN FRANCE
Beate Jahn, PhD1, Gaby Sroczynski, MPH, Dr.PH1, Annette Conrads-Frank, PhD1, Gregoire Jeanblanc, MD2, Aurore Duguet, PharmD2, Derek Misurski, PhD3, Jennifer Samp, PHARMD, MS3 and Uwe Siebert, MD, MPH, MSc, ScD4, (1)Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i.T., Austria, (2)AbbVie Inc., Rungis, France, (3)AbbVie Inc., North Chicago, IL, (4)UMIT, Dept. of Public Health, Health Services Research and Health Technology, Hall in Tirol, Austria
PS4-4

COMPARISON OF EQ-5D AND SF-6D BASED COST-EFFECTIVENESS ANALYSIS OF HAEMODIALYSIS AND PERITONEAL DIALYSIS TREATMENTS
Fan Yang, PhD1, Brenda Gannon, PhD1 and Nan Luo, PhD2, (1)Manchester Centre for Health Economics, University of Manchester, Manchester, United Kingdom, (2)Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
PS4-5

TRANSFORMING THE COST-EFFECTIVENESS THRESHOLD INTO A 'VALUE THRESHOLD': INITIAL FINDINGS FROM A SIMULATION MODEL
Mike Paulden, MA., MSc., University of Alberta, Edmonton, AB, Canada and Christopher McCabe, PhD, Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada
PS4-6

COMPARING YOUNG AND OLDER ITALIAN WOMEN ON PREFERENCES FOR BRCA TESTING AND RISK REDUCTION AND MANAGEMENT STRATEGIES
Teresa Gavaruzzi1, Alessandra Tasso2, Marzena Franiuk3, Liliana Varesco3 and Lorella Lotto1, (1)DPSS, University of Padova, Padova, Italy, (2)University of Ferrara, Ferrara, Italy, (3)IRCCS AOU San Martino, Genova, Italy
PS4-7

THE USE OF BEST-WORST SCALING CASE 2 TO ESTIMATE INDIVIDUALIZED PREFERENCES FOR VALUE CLARIFICATION AND DECISION SUPPORT
Marieke G.M. Weernink, MSc1, Marije van der Straten, MSc1, Paul J.M. Kil, MD, PhD2, Jeroen P.P. van Vugt, PhD3, Maarten J. IJzerman, PhD1 and Janine A. van Til, PhD1, (1)University of Twente, Enschede, Netherlands, (2)St. Elisabeth Hospital, Tilburg, Netherlands, (3)Department of Neurology, Medical Spectrum Twente, Enschede, Netherlands
PS4-8

ONTOLOGY DRIVEN DECISION SUPPORT FOR EARLY DIAGNOSTIC RECOMMENDATIONS
Gopikrishnan Mannamparambil Chandrasekharan, B.D.S, M.Sc, Dympna O'Sullivan, PhD and Andrew MacFarlane, PhD, City University London, London, United Kingdom
PS4-10

A SYSTEMATIC REVIEW OF ETHNICITY-SPECIFIC FACTORS INFLUENCING CHILDHOOD IMMUNISATION DECISIONS AMONG BLACK AND ASIAN MINORITY ETHNIC GROUPS IN THE UK
Alice Forster, BSc, MSc, PhD1, Lauren Rockliffe, BSc, MSc1, Amanda Chorley, BSc, MSc1, Laura Marlow, BSc, MSc, PhD1, Helen Bedford, RGN, BSc, MSc, PhD1, Samuel Smith, BSc, MSc, PhD2 and Jo Waller, BA, MSc, PhD1, (1)UCL, London, United Kingdom, (2)Queen Mary University of London, London, United Kingdom
PS4-11

INTER-OBSERVER AGREEMENT IN LUNG SOUND CLASSIFICATION AIDED BY VISUAL REPRESENTATION OF THE SOUNDS
Juan Carlos Aviles Solis, MD, General Practice Reseach Unit, Tromso¸, Norway, Peder A. Halvorsen, MD, PhD, Department of Community Medicine, UiT - The Arctic University of Norway, Tromsø, Norway and Hasse Melbye, MD, PhD, General Practice Reseach Unit, Tromso, Norway
PS4-12

DECISION-MAKING SUPPORT AT THE PATIENT RELATIONS OFFICE OF AN ADVANCED TREATMENT HOSPITAL IN JAPAN
Yukari Yamamoto, RN, MPH, Shiho Urakawa, MD, MA and Yoshiyuki Takimoto, MD, Ph.D, The University of Tokyo, Tokyo, Japan
PS4-13

MODELLING ETELCALCETIDE EFFECTIVENESS ON HEALTH OUTCOMES: RELATING BIOCHEMICAL OUTCOMES TO MORTALITY, CARDIOVASCULAR EVENTS, FRACTURES AND PARATHYROIDECTOMY
Björn Stollenwerk, PhD1, Andrew Briggs, DPhil2, Bastian Dehmel, MD3, Ron Akehurst, BSc (Econ) (London), Hon MFPHM4, Patrick Parfrey, MD, FRCPC, OC, FRSC5, Sergio Iannazzo, PhD6, Michael Adena, PhD7 and Vasily Belozeroff, PhD3, (1)Amgen (Europe) GmbH, Zug, Switzerland, (2)University of Glasgow, Glasgow, United Kingdom, (3)Amgen Inc., Thousand Oaks, CA, (4)BresMed, Sheffield, United Kingdom, (5)Memorial University, St. John's, NF, Canada, (6)SIHS Health Economics Consulting, Torino, Italy, (7)Datalytics Pty Ltd, Bruce ACT, Australia
PS4-14

NEW MODEL OF HEALTHCARE DELIVERY: TELEHOMECARE PROGRAM FOR HEART FAILURE (HF) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS IN ONTARIO, CANADA
Valeria E. Rac, MD, PhD1, Yeva Sahakyan, MD, MPH2, Nida Shahid, HBSc., MSc (c.)2, Aleksandra Stanimirovic, MSc, PhD (candidate)2, Iris Fan, BA1, Welson Ryan2 and Murray D. Krahn, MD, MSc3, (1)Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada, (2)Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, ON, Canada, (3)University of Toronto and University Health Network, Toronto General Research Institute, Toronto Health Economics and Technology Assessment (THETA) Collaborative, Toronto, ON, Canada
PS4-15

MONITORING PRIMARY CARE - DEVELOPMENT OF DATA BASED INDICATORS FOR THE AUSTRIAN HEALTH SYSTEM
Niki Popper, PhD, dwh Simulation Services /Technical University Vienna, Institute for Analysis and Scientific Computing / DEXHELPP (Decision Support for Health Policy and Planning), Vienna, Austria, Barbara Glock, MSc, dwh Simulation Services, Wien, Austria, Matthias Schauppenlehner, Mag., Main Association of Social Insurances, Vienna, Austria and Harald Piringer, Dr., VRVis Zentrum fuer Virtual Reality und Visualisierung Forschungs-GmbH, Vienna, Austria
PS4-16

NON-INVASIVE PRENATAL TESTING: FACILITATING AUTONOMY OR COMPLICATING DECISION MAKING?
Jeffrey Wale, LLB (Hons); PGCE, Bournemouth University, Poole, United Kingdom of Great Britain and Northern Ireland
PS4-17

THE EFFECT OF THINKING TIME ON ATTRIBUTE NON-ATTENDANCE IN DISCRETE CHOICE EXPERIMENTS: AN EYE-TRACKING STUDY
Kate Mandeville1, Benjamin Cooper2, Sian Martin2, Mylene Lagarde1, Stian Reimers2 and Kielan Yarrow2, (1)London School of Hygiene and Tropical Medicine, London, United Kingdom, (2)City University London, London, United Kingdom
PS4-18

ASSOCIATION OF DISEASE PROGRESSION, HEALTH-RELATED QUALITY OF LIFE, AND UTILITY IN PATIENTS WITH ADVANCED, NONFUNCTIONAL, WELL-DIFFERENTIATED GASTROINTESTINAL OR LUNG NEUROENDOCRINE TUMORS IN THE PHASE 3 RADIANT-4 TRIAL
Simron Singh, MD1, Marianne E. Pavel, MD2, Jonathan Strosberg, MD3, Lida Bubuteishvili-Pacaud, MD4, Evgeny Degtyarev, MSc4, Maureen P. Neary, PhD5, Matthias Hunger, PhD6, Jennifer Eriksson, MSc7, Nicola Fazio, MD8, Matthew Kulke, MD9 and James C. Yao, MD10, (1)Sunnybrook Health Sciences Centre, Toronto, ON, Canada, (2)Charité Berlin Campus Virchow-Klinikum, Berlin, Germany, (3)Department of Medicine, Moffitt Cancer Center, Tampa, FL, (4)Novartis Pharma AG, Basel, Switzerland, (5)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (6)Mapi, Munich, Germany, (7)Mapi, Stockholm, Sweden, (8)Istituto Europeo di Oncologia IRCCS, Milan, Italy, (9)Dana Farber Cancer Institute, Boston, MA, (10)University of Texas MD Anderson Cancer Center, Houston, TX
PS4-19

DISCRETE EVENT SIMULATION MODELLING TO ANALYSE INNOVATIONS IN CANCER PATHOLOGY SERVICES
Asmaa El-Banna, MSc1, Jason Madan, MA, MSc, PhD1 and Ian Cree2, (1)University of Warwick, Coventry, United Kingdom, (2)University Hospitals Coventry and Warwickshire, Coventry, United Kingdom
See more of: 16th Biennial European Conference
<< Previous Session | Next Session >>